Want to see HK:1513 full AI Analyst Report?
Top Page
Livzon Pharmaceutical Group
(1513)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$23.00
▲(13.86% Upside)
Action:Reiterated
Date:08/25/26
The score is primarily supported by strong profitability, strong free cash flow, and conservative leverage, alongside an attractive dividend yield. These positives are meaningfully offset by very weak technicals (price below all major moving averages with depressed RSI/Stoch) and the reported TTM revenue decline, which together signal near-term momentum and growth headwinds.
Positive Factors
Resilient Profitability
High and broadly stable margins indicate pricing power, product mix resilience, and disciplined cost control. This profitability base should help Livzon fund research, commercial expansion, and shareholder returns even while revenue growth remains uneven.
Negative Factors
Revenue Contraction
Sustained revenue weakness points to pressure on demand, product mix, or market access and could limit operating leverage. If contraction persists, it may reduce the resources available for pipeline investment and make margin preservation more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Resilient Profitability
High and broadly stable margins indicate pricing power, product mix resilience, and disciplined cost control. This profitability base should help Livzon fund research, commercial expansion, and shareholder returns even while revenue growth remains uneven.
Read all positive factors
Livzon Pharmaceutical Group (1513) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$24.12B
Dividend Yield8.16%
Average Volume (3M)553.85K
Price to Earnings (P/E)13.9
Beta (1Y)0.78
Revenue Growth-5.90%
EPS Growth-18.84%
CountryHK
Employees8,878
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.89
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio8.43
Price to Book (P/B)1.65
Price to Sales (P/S)1.90
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.00Price Target Upside43.56% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.23
Revenue Forecast (FY)HK$11.30B
Livzon Pharmaceutical Group Business Overview & Revenue Model
Company Description
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs...
How the Company Makes Money
null...
Livzon Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.70B | 12.02B | 11.81B | 12.43B | 12.63B | 12.06B |
| Gross Profit | 6.72B | 7.92B | 7.73B | 7.66B | 8.17B | 7.81B |
| EBITDA | 2.70B | 3.10B | 3.47B | 3.33B | 3.08B | 2.77B |
| Net Income | 1.67B | 2.02B | 2.06B | 1.95B | 1.91B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 23.59B | 24.00B | 24.46B | 25.04B | 24.86B | 22.37B |
| Cash, Cash Equivalents and Short-Term Investments | 8.19B | 10.93B | 10.92B | 11.41B | 10.52B | 9.33B |
| Total Debt | 4.24B | 3.85B | 3.93B | 3.48B | 3.62B | 2.69B |
| Total Liabilities | 8.76B | 8.20B | 9.55B | 10.28B | 9.93B | 8.06B |
| Stockholders Equity | 13.36B | 13.89B | 13.86B | 14.04B | 13.88B | 13.00B |
Cash Flow | ||||||
| Free Cash Flow | 2.90B | 2.54B | 2.41B | 2.43B | 1.83B | 593.23M |
| Operating Cash Flow | 3.30B | 3.10B | 2.98B | 3.25B | 2.77B | 1.90B |
| Investing Cash Flow | -3.71B | -3.67B | -660.33M | -708.37M | -1.23B | -1.88B |
| Financing Cash Flow | -2.38B | -2.62B | -2.49B | -1.66B | -720.36M | -815.02M |
Livzon Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$17.28B | 6.54 | 12.65% | 3.29% | -4.09% | -22.73% | |
69 Neutral | HK$24.12B | 13.90 | 13.95% | 6.34% | -5.90% | -18.84% | |
68 Neutral | HK$28.81B | 6.15 | 7.92% | 2.95% | 7.94% | 52.83% | |
61 Neutral | HK$28.23B | 15.90 | 8.60% | 2.70% | 14.80% | -2.88% | |
60 Neutral | HK$18.81B | 16.41 | 7.26% | 3.21% | 7.35% | -45.49% | |
59 Neutral | HK$36.67B | 12.95 | 6.54% | 6.12% | 6.58% | -4.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1513
Livzon Pharmaceutical Group
20.14
-13.17
-39.54%
HK:3933
The United Laboratories International Holdings
8.69
-5.62
-39.25%
HK:0867
China Medical System Holdings
11.51
-1.15
-9.08%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
14.11
-3.30
-18.98%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.61
-0.06
-1.26%
HK:0512
Grand Pharmaceutical Group Limited
5.26
-3.51
-40.00%
Livzon Pharmaceutical Group Corporate Events
Livzon Pharma Raises Stake in Xinbeijiang Unit Through Connected Share Deal
Aug 21, 2026
Livzon Pharmaceutical Group has agreed to acquire approximately 3.50% of the shares in Xinbeijiang Pharma from Zhong Hui Yuan for about RMB 106.70 million in cash. Upon completion, Livzon’s direct shareholding in Xinbeijiang Pharma will rise...
Livzon Pharmaceutical Group Publishes Unaudited 2026 Interim Results
Aug 21, 2026
Livzon Pharmaceutical Group has released its unaudited interim results for the six months ended 30 June 2026, providing shareholders and investors with a comprehensive update on its mid‑year financial and operational performance. The full in...
Livzon Pharmaceutical Schedules Board Meeting for Interim Results Review
Aug 6, 2026
Livzon Pharmaceutical Group has scheduled a board meeting for 21 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also address other business matters, signaling the next formal...
Livzon Subsidiary’s Ankylosing Spondylitis Drug Application Accepted by China’s NMPA
Jun 1, 2026
Livzon MABPharm, a subsidiary of Livzon Pharmaceutical Group, has had its marketing authorization application for Lecankitug Injection formally accepted for review by China’s National Medical Products Administration. The domestically develop...
Livzon Wins NMPA Approval for Biosimilar Fertility Drug
Jun 1, 2026
Livzon MAB Pharm, a subsidiary of Livzon Pharmaceutical Group, has obtained a drug registration certificate from China’s National Medical Products Administration for its independently developed Recombinant Human Follitropin Alfa Solution for...
Livzon Pharmaceutical Wins Shareholder Backing for All 2025 AGM and 2026 Class Meeting Resolutions
May 29, 2026
Livzon Pharmaceutical Group reported that its 2025 annual general meeting and the first 2026 class meetings for A and H shareholders were held on 29 May 2026 in Zhuhai, Guangdong, with all resolutions duly approved by poll. The company detailed th...
Livzon Pharmaceutical Revamps Board and Affirms Director Independence
May 29, 2026
Livzon Pharmaceutical Group has completed a broad refresh of its twelfth-session board, with shareholders approving the re-election of several non-executive directors and independent non-executive directors, while confirming a consistent remunerat...
Livzon Pharmaceutical Outlines Board and Committee Structure in Governance Update
May 29, 2026
Livzon Pharmaceutical Group has detailed the current composition of its board of directors, listing executive, non-executive, independent and employee representative members and their respective leadership roles. The announcement also clarifies wh...
Livzon Pharmaceutical Declares Final 2025 Dividend and Sets Hong Kong Payout Details
May 29, 2026
Livzon Pharmaceutical Group Inc. has declared a final ordinary cash dividend of RMB 14.3 per 10 shares for the financial year ended 31 December 2025, with shareholders approving the payout on 29 May 2026. The dividend will be paid to Hong Kong sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.